A Study Exploring the Use of Challenge Agents in Healthy Volunteers or Participants With a Disease of Interest

Healthy Clinical Trial

Official title:

A Phase 0 Platform Study Exploring the Use of Challenge Agents in Healthy Volunteers or Participants With a Disease of Interest

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05007756
• Other study ID #: CR109034
• Secondary ID: NOPRODPCNAP0002P
• Status: Completed
• Phase: Early Phase 1
• Start date: July 14, 2021
• Est. completion date: November 4, 2021

Study information

• Verified date: December 2021
• Source: Janssen Research & Development, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the biological response in vivo to challenge agents (vaccines, antigen, drug, or mechanical challenges); to assess the safety and tolerability of the challenge agent and to characterize the immune response in skin elicited in vivo in healthy volunteers using an ultraviolet B (UVB) challenge.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: November 4, 2021
• Est. primary completion date: November 4, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-HCG]) at screening and a negative urine pregnancy test prior to study intervention administration on Day -4

• Must have Fitzpatrick skin type II or III (10 participants) or type IV or higher (2 participants)

• Otherwise healthy on the basis of physical examination, medical history, and vital signs, and, if required by the applicable Intervention Specific Appendix (ISA), a 12-lead Electrocardiography (ECG) performed at screening. Any abnormalities must be considered not clinically significant or consistent with the underlying illness in the study population and this determination must be recorded

• Otherwise healthy on the basis of clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges, the participant may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically significant or to be appropriate and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator

• Must be a non-smoker (not smoked for at least 6 months prior to screening) and has not used nicotine-containing products (example, nicotine patch) for 3 months prior to screening

Exclusion Criteria:

• Has a history of dysplastic melanocytic nevi or skin cancer

• Known hypersensitivity, intolerance to UV/sunlight exposure, or any condition associated with photosensitivity

• Has Fitzpatrick skin type I, as determined by the investigator. A person with Fitzpatrick skin type I typically has unexposed skin that is bright white with frequent freckling, has blue/green eyes, and is of Northern European/British descent. They typically burn, peel, and don't tan in response to ultraviolet B (UVB)

• Has a history of chronic skin conditions, such as vitiligo, psoriasis, rosacea, severe eczema, or atopic dermatitis, and/or severe acne that would complicate or preclude evaluation of the minimal erythema dose (MED) testing and UVB challenge sites

• Has used topical antibiotics or topical corticosteroids within 1 month prior to study intervention administration and/or has a history of extensive and prolonged use (greater than [>] 3 months) of topical antibiotics or topical corticosteroids

Related Conditions & MeSH terms

• Healthy

Intervention

Radiation:
• UVB Challenge
UVB challenge will be administered dermally through Lumera Phototherapy System.

Locations

Country	Name	City	State
Belgium	Clinical Pharmacology Unit	Merksem

Sponsors (1)

Lead Sponsor	Collaborator
Janssen Research & Development, LLC

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Changes in Gene Expression as Measured by Counts of Transcript per Million Reads	Changes in gene expression as measured by counts of transcript per million reads in control versus challenged tissue will be reported.	Up to Week 6
Primary	Changes in Gene Set Variation Analysis Enrichment Score	Changes in gene set variation analysis (GSVA) enrichment score control versus challenged tissue will be reported. The GSVA score is a measurement of changes in a set of genes between 2 sample sets (example, control versus test).	Up to Week 6
Primary	Changes in Cell Count as Measured by Fluorescence Intensity	Changes in cell count as measured by fluorescence intensity via immunohistochemistry (IHC) in control versus challenged tissue will be reported.	Up to Week 6
Primary	Changes in Protein Expression as Measured by Fluorescence Intensity	Changes in protein expression as measured by fluorescence intensity via IHC in control versus challenged tissue will be reported.	Up to Week 6
Primary	Changes in Gene Expression as Measured by Fluorescence Intensity	Changes in gene expression as measured by fluorescence intensity via IHC in control versus challenged tissue will be reported.	Up to Week 6
Primary	Changes in the Levels of Proteins and Phosphoproteins	Changes in the levels of proteins and phosphoproteins which are relevant to inflammatory pathways thought to be activated by ultraviolet B (UVB) exposure (example, Type 1 interferons pathways) measured by enzyme-linked immunoassay (ELISA) in control versus challenged tissue lysates, will be reported.	Up to Week 6
Primary	Fold Changes in the Mean Differences of the Levels of Proteins and Phosphoproteins	Fold changes in the mean differences of the levels of the proteins and phosphoproteins which are relevant to inflammatory pathways thought to be activated by UVB exposure (example, type 1 interferons pathways) measured by ELISA in control versus challenged tissue lysates, will be reported.	Up to Week 6
Primary	Number of Participants with Treatment-emergent Adverse Events (TEAEs)	An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.	Up to Week 6
Primary	Number of Participants with Treatment-emergent Serious Adverse Events (SAEs).	A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent SAEs are defined as serious events between administration of study drug and after the last dose that were absent before treatment or that worsen relative to pretreatment state.	Up to Week 6
Primary	Number of Participants with TEAEs by Medical Dictionary for Regulatory Activities (MedDRA) System-organ Class (SOC) with a Frequency Threshold of at Least 2 Participants per Intervention Cohort	Number of participants with TEAEs by MedDRA SOC with a frequency threshold of at least 2 participants per intervention cohort will be reported. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment.	Up to Week 6
Secondary	Standard Deviation of Changes in Gene Expression as Measured by Counts of Transcript per Million Reads	Standard deviation of changes in gene expression as measured by counts of transcript per million reads in control versus challenged tissue will be reported.	Up to Week 6
Secondary	Standard Deviation of Changes in GSVA Enrichment Score	Standard deviation of changes in GSVA enrichment score will be reported. The GSVA score is a measurement of changes in a set of genes between 2 sample sets (example, control versus test).	Up to Week 6
Secondary	Standard Deviation of Changes in Cell Count as Measured by Fluorescence Intensity	Standard deviation of changes in cell count as measured by fluorescence intensity via IHC in control versus challenged tissue will be reported.	Up to Week 6
Secondary	Standard Deviation of Changes in Protein Expression as Measured by Fluorescence Intensity	Standard deviation of changes in protein expression as measured by fluorescence intensity via immunohistochemistry (IHC) in control versus challenged tissue will be reported.	Up to Week 6
Secondary	Standard Deviation of Changes in Gene Expression as Measured by Fluorescence Intensity	Standard deviation of changes in gene expression as measured by fluorescence intensity via IHC in control versus challenged tissue will be reported.	Up to Week 6
Secondary	Standard Deviation of Changes in Phosphoproteins and Other Proteins	Standard deviation of changes in phosphoproteins and other proteins in tissue lysate in control versus challenged tissue will be reported.	Up to Week 6
Secondary	Standard Deviation of Fold Changes of Means of Phosphoproteins and Other Proteins	Standard deviation of fold changes of means of phosphoproteins and other proteins in control versus challenged tissue will be reported.	Up to Week 6

External Links

•   To learn how to participate in this trial please click here.